"A planned March 13 meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee on the influenza vaccine strains for the 2025-2026 influenza season in the northern ...
In response, the FDA agreed with Adial’s proposed 505(b)(2) bridging strategy, which involves leveraging the results from AD04-103—a relative bioavailability food-effect study—along with in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback